Coherus Biosciences | CHRS - Capitale Ordinario





Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 1.75B 2025-06
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Akebia Therapeutics USD 265.42M 199K 2025-12
ALKERMES USD 166.46M 855K 2026-03
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Amarin USD 20.81M 13K 2025-12
Amgen USD 540M 1000K 2026-03
Baxter International USD 516.45M 2.17M 2026-03
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Fujifilm JPY 1.21B 33K 2026-03
Gilead Sciences USD 1.24B 1000K 2026-03
Ironwood Pharmaceuticals USD 160K 0 2024-12
Merck USD 2.47B 12.72M 2025-12
Myriad Genetics USD 93.5M 400K 2025-12
Pacira USD 39.31M 1.81M 2026-03
Perrigo USD 138.1M 500K 2026-03
Pfizer USD 5.7B 13M 2026-03
PTC Therapeutics USD 81.47M 1.54M 2025-12
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sarepta Therapeutics USD 105.57M 607K 2026-03
Teva Pharmaceutical Industries USD 1.16B 16.72M 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03
Xencor USD 74.06M 2.19M 2026-03
Zoetis USD 420.35M 4.58M 2026-03